注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
上海復宏漢霖生物技術股份有限公司是一家主要從事單克隆抗體產品的研發、生產及銷售業務的中國公司。該公司的主要產品包括利妥昔單抗注射液HLX01(漢利康)、赫賽汀(曲妥珠單抗)生物類似藥HLX02、修美樂(阿達木單抗)生物類似藥HLX03和安維汀(貝伐珠單抗)生物類似藥HLX04以及候選生物創新藥,包括HLX06(一種新型VEGFR2抑制劑)、HLX07(一種EGFR抑制劑)、HLX10(一種新型PD-1抑制劑)、HLX20(一種新型PD-L1抑制劑)及HLX22(一種新型HER2抑制劑)等。該公司還提供相關技術服務。該公司主要在中國境内和美國開展業務。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Xiaohui Guan | 53 | 2018 | Non-Executive Director |
Lik Yuen Chan | 56 | 2019 | Independent Non-Executive Director |
Tak Young So | 53 | 2019 | Independent Non-Executive Director |
Ruilin Song | 60 | 2019 | Independent Non-Executive Director |
Guoping Zhao | 75 | 2019 | Independent Non-Executive Director |
Deli Kong | 50 | 2016 | Supervisor |
Qiyu Chen | 52 | 2013 | Non-Executive Director |
Rongli Feng | 49 | 2020 | Chairman of Supervisory Board |
Alberto Mantovani | - | 2023 | Member of Scientific Advisory Board |
Yifang Wu | 55 | 2015 | Non-Executive Director |
David R. Gandara | 76 | 2023 | Member of Scientific Advisory Board |
Abul K. Abbas | - | 2023 | Member of Scientific Advisory Board |
K. Christopher Garcia | - | 2023 | Member of Scientific Advisory Board |
Yexing Yuan | 40 | 2023 | Supervisor |
Deyong Wen | 53 | 2022 | Non-Executive Director |
Xingli Wang | - | 2023 | Non-Executive Director |
Yangxin Fu | - | - | Member of Scientific Advisory Board |
Lixin Zhang | - | - | Member of Scientific Advisory Board |
Wenjie Zhang | 57 | 2019 | Executive Chairman of the Board |
Jun Zhu | 45 | 2021 | CEO, CFO & Executive Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核